MAPT and Alzheimer disease: Moreover, because these p-tau biomarkers are associated with the emergence of Aβ pathology, even from the earliest stages of preclinical AD [31, 33, 46, 65, 66], it is difficult to determine later in the disease course, what is the contribution of tau deposition to the overall p-tau signal in blood.